首页> 美国卫生研究院文献>Respirology Case Reports >Successful management of pleural infection with very low dose intrapleural tissue plasminogen activator/deoxyribonuclease regime
【2h】

Successful management of pleural infection with very low dose intrapleural tissue plasminogen activator/deoxyribonuclease regime

机译:用极低剂量的胸膜内组织纤溶酶原激活剂/脱氧核糖核酸酶方案成功治疗胸膜感染

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Pleural infection managed with intrapleural therapy using a combination of 10 mg of tissue plasminogen activator (tPA) and 5 mg of deoxyribonuclease (DNase) has been shown in randomized and open‐label studies to successfully treat >90% of patients without resorting to surgery. Potential bleeding risks, although low, and costs associated with tPA remain important concerns. No phase I studies exist for intrapleural tPA therapy and the lowest effective dose has not been established. In patients with high bleeding risks, lower doses may present a safer alternative. We report a case of a complex parapneumonic effusion in a patient with coagulopathy that was successfully treated with a very low dose tPA (1 mg) and DNase (5 mg) regime.
机译:随机和开放标签研究显示,胸膜内治疗结合使用10 mg组织纤维蛋白溶酶原激活剂(tPA)和5 mg脱氧核糖核酸酶(DNase)处理的胸膜感染可成功治疗90%以上的患者而无需手术。潜在的出血风险虽然较低,但与tPA相关的成本仍然是重要的问题。目前尚无用于胸膜内tPA治疗的I期研究,并且尚未确定最低有效剂量。在出血风险高的患者中,较低剂量可能是更安全的选择。我们报告了一个患有凝血病的复杂肺炎旁积液病例,该病已通过非常低剂量的tPA(1 mg)和DNase(5 mg)方案成功治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号